Connect with us

Technology

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Published

on

LONDON, Feb. 27, 2024 /PRNewswire/ — C the Signs, a British AI technology company founded by NHS Doctors at the forefront of early cancer detection, has been announced as part of the inaugural cohort of the White House CancerX Accelerator programme.

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology. The initiative aims to achieve the ambitious ‘Cancer Moonshot’ goals set by the administration: to reduce cancer mortality by at least 50% over the next 25 years, and to enhance the quality of life for individuals and families living with and surviving cancer. The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.

C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease. It has so far detected over 25,000 patients with cancer through its innovative AI approach, with a 98% accuracy in ruling in or out cancer risk.  It was selected as one of 16 companies – and the only British company – to be part of the first CancerX Accelerator, C the Signs was selected as it represents one of the most progressive and effective ways of driving digital innovation in oncology.

Dr. Bea Bakshi, CEO & Co-Founder of C the Signs, says:

“As a doctor, I am deeply moved and profoundly grateful for our selection to participate in the inaugural CancerX accelerator. Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot’s vision of a 50% reduction in cancer mortality. At C the Signs, our mission is firmly rooted in the belief that early detection can change the course of this disease, aiming for a future where surviving cancer is the norm rather than the exception. The success we’ve achieved within the UK’s National Health Service so far fills me with immense pride and hope. As we embark on this journey in the United States, I am incredibly enthusiastic about collaborating with the brightest minds in oncology and industry pioneers; what we can collectively achieve is boundless. This is more than just an opportunity; it’s a pivotal moment to lead with heart and affect meaningful change.”

Aphrodite Spanou, Director of Healthcare UK, Department of Health and Social Care, NHS England and the Department for Business and Trade, says:

“We are delighted for C the Signs for being selected as one of the inaugural companies, by the White House’s CancerX Accelerator. This recognition is a testament to the UK’s leadership in healthcare innovation and our capacity to create technology solutions with a global impact. C the Signs’ work in early cancer detection not only exemplifies British ingenuity but also aligns perfectly with our objectives of showcasing how local innovations can have international reach and significance.”

C the Signs was selected from hundreds of applicants after an intensive evaluation process involving three rounds of judging and will now have the unprecedented opportunity to collaborate with the CancerX Champions from leading cancer and technology innovators including AstraZeneca, Intel, Dell Technologies, AWS, Debiopharm Innovation Fund, Mass Challenge, Reveal HealthTech, Atrium Health, Oncology Ventures, and UC Davis Health.

NOTES FOR EDITORS:

ABOUT CANCERX:
Part of the U.S. Cancer Moonshot initiative, CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer. Co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center, alongside the Office of the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), it convenes the many diverse stakeholders needed to unleash the power of innovation to create a future that’s free of cancer burden. To learn more or participate in CancerX’s pre-competitive, evidence-generating efforts; Accelerator cohort; or demonstration projects, visit www.cancerx.health

ABOUT THE CANCERX ACCELERATOR:
The CancerX Accelerator program aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations. Startup participants benefit from valuable mentorship, comprehensive training and direct access to key players in the health care industry, including providers, payers and pharmaceutical companies. This collaborative environment enables startups to develop, test and implement their cancer focused innovation on a larger scale.
https://cancerx.health/accelerator/

ABOUT THE 16 START-UPS:
A team of Accelerator Champions and judges from the CancerX community led three rounds of judging earlier this year to select this impressive cohort group. The full list of startups includes: The Blue Box, C the Signs, Cancer Insights, Curvia, EnteroTrack, Gesund.ai, Gray Oncology, LindAI, Mika Health, Navya, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, and Xanthos.

ABOUT THE PROGRAMME:

As a member of the CancerX accelerator, start-ups will now participate in a rich, 4-month program where they will:

Engage with members of the healthcare ecosystem to test and validate their solutions.Get expert guidance from CancerX Mentors.Graduate with a roadmap to successfully scale our company, an opportunity to move forward with our sponsor, and a community that will continue to support our development.

FURTHER INFORMATION:

–  For further information on The White House Cancer Moonshot Announcement
https://www.whitehouse.gov/briefing-room/statements-releases/2022/02/02/fact-sheet-president-biden-reignites-cancer-moonshot-to-end-cancer-as-we-know-it/#:~:text=Based%20on%20the%20progress%20made%20and%20the%20possibility,and%20their%20families%20living%20with%20and%20surviving%20cancer.
–  For further questions or queries on CancerX: laura@dimesociety.org
–  For the CancerX logo (Horizontal + Vertical)
–  For further information on C the Signs: www.cthesigns.com
–  For further information for press or media queries please contact: Charlotte Beams, Communications Officer, charlottebeames@cthesigns.net

ABOUT HEALTHCARE UK:

Healthcare UK is a joint initiative of the Department of Health and Social Care, NHS England and the Department for Business and Trade. Healthcare UK promotes the British healthcare sector internationally to drive export opportunities and works with the NHS to strengthen its capacity to operate and succeed internationally.

View original content:https://www.prnewswire.com/news-releases/british-technology-company-c-the-signs-selected-by-the-white-house-backed-accelerator-programme-cancerx-to-half-cancer-deaths-302071760.html

SOURCE C the Signs

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

RTX’s Pratt & Whitney Valox™ 1500 Engine Completes Key Design Milestone

Published

on

By

Valox 1500 design set to deliver an optimal mix of affordability, performance and speed to market for autonomous platforms

LONDON, July 21, 2026 /PRNewswire/ — Farnborough International Airshow — Pratt & Whitney, an RTX (NYSE: RTX) business, has successfully completed a key design milestone for its Pratt & Whitney Valox™ 1500 engine, a new powerplant intended for semi-autonomous collaborative platforms. A comprehensive digital assessment confirms the design is on track to deliver an optimal mix of performance, affordability, and speed to market.

“This milestone reflects Pratt & Whitney’s agility and commitment to delivering critical capability to the warfighter at speed,” said Jill Albertelli, president of Pratt & Whitney’s Military Engines business. “By optimizing the engine design for reduced mission life and moving beyond traditional development timelines, our team is bringing forward a more affordable, scalable propulsion solution for emerging operational needs.”

Leveraging proactive investments in digital engineering, Pratt & Whitney has significantly de-risked the development timeline and is now focused on maturing the design for follow-on ground testing. In late 2025, Pratt & Whitney received a contract award valued at more than $10 million from the U.S. Air Force to advance the engine design.

Pratt & Whitney recently unveiled the Pratt & Whitney Valox™ engine family, which is engineered to deliver the speed, precision, and affordability required for modern collaborative combat systems and a broad range of emerging applications.

About Pratt & Whitney
Pratt & Whitney, an RTX business, is a world leader in the design, manufacture and service of aircraft engines and auxiliary power units for military, commercial and civil aviation customers. Since 1925, our engineers have pioneered the development of revolutionary aircraft propulsion technologies, and today we support more than 90,000 in-service engines through our global network of maintenance, repair and overhaul facilities.

About RTX
With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.

For questions or to schedule an interview, please contact corporatepr@rtx.com

 

View original content:https://www.prnewswire.com/news-releases/rtxs-pratt–whitney-valox-1500-engine-completes-key-design-milestone-302830230.html

SOURCE RTX

Continue Reading

Technology

CLO zFab Kit Now Available Globally: AI-Powered Fabric Digitization, No CLO License Required

Published

on

By

Standalone solution available via CLO-SET brings fast and accurate cutting-edge fabric digitization technology to brands, vendors, fabric mills and supply chain partners worldwide

NEW YORK, July 21, 2026 /PRNewswire/ — CLO Virtual Fashion today announced the availability of the CLO zFab Kit, a revolutionary AI-powered fabric digitization solution, now available for order and shipping to customers worldwide. The biggest news for the industry: the CLO zFab Kit can operate as a standalone solution without needing access to the CLO software to operate. Brands, vendors, fabric mills, fabric agents, and supply chain partners can digitize fabrics with full accuracy and produce ready-to-use digital materials via the web using CLOFAB via CLO-SET; a CLO software license is not needed.

“We’ve been eager to come up with ways to address some of the pain points of fabric digitization that our users and clients were going through. Quality was inconsistent, devices were slow and difficult to operate, pricey and often locked behind specialist workflows,” said Justin Kim, 3D Design & Implementation at CLO. “The CLO zFab Kit closes the gap. And by making it truly standalone via the web on CLO-SET, we’re putting accurate digital fabric in reach of the entire supply chain, not just the design teams already using CLO.”

What the CLO zFab Kit Delivers

The CLO zFab Kit combines three pieces of purpose-built hardware (zFab Cutter, zFab Scanner and zFab Draper) with CLO’s AI-powered software to capture a fabric’s physical and visual properties from a single circular sample. The output is a high-fidelity digital fabric, including PBR maps and physical property data, ready to drop into any workflow.

Three things set it apart:

Superior Accuracy. Replaces error-prone manual measurement with a streamlined cutting, scanning and analysis system, producing digital fabrics that can effectively drive production decisions.AI-driven Automation. Powered by proprietary AI and trained on CLO and swatchbook’s extensive fabric dataset, the CLO zFab Kit speeds up digitization while keeping results consistent across operators and locations.Seamless Integration. Outputs work natively in CLO’s platform and export cleanly to other 3D environments – no rework, no format gymnastics.

 

Built for the Fashion Supply Chain

While the CLO zFab Kit perfectly complements design teams using the CLO software, it was purposefully built with fabric mills, vendors, sourcing teams, and material libraries in mind. By providing suppliers with the best tools to create high-quality digital fabrics quickly, easily and consistently, the CLO zFab Kit can help cut physical sample shipments, shortens material approval cycles, and gives everyone in the workflow chain cleaner and better data to decide and act with more confidence.

The CLO zFab Kit is available globally for ordering today. It does not require CLO licenses to operate and use. Pricing, configuration, demo requests, and how-to-use tutorials are available at zfabkit.clo3d.com

About CLO Virtual Fashion

CLO Virtual Fashion is the creator of CLO, the leading 3D fashion design software used and trusted by designers, small businesses, and titans of the fashion industry to achieve a seamless digital workflow. With over two decades of research and development in accurate garment simulation, CLO Virtual Fashion’s mission is to empower users at every step of the garment journey, from concept to design, manufacturing to marketing, and fitting to styling. In addition to 3D garment design software, CLO Virtual Fashion’s products include CLO-SET (a cloud-based asset management and collaboration platform), CONNECT (a digital fashion hub and marketplace), and consumer-facing solutions such as e-commerce virtual fittings. CLO’s interconnected and ever-growing product ecosystem is built to power the future of everything related to garments.

View original content to download multimedia:https://www.prnewswire.com/news-releases/clo-zfab-kit-now-available-globally-ai-powered-fabric-digitization-no-clo-license-required-302830468.html

SOURCE CLO Virtual Fashion

Continue Reading

Technology

Arcfra Releases Neutree 1.1 to Help Enterprises Optimize GPU Utilization and Govern AI Inference at Scale

Published

on

By

SINGAPORE, July 21, 2026 /PRNewswire/ — Arcfra today announced the release of Neutree 1.1, a Model-as-a-Service platform for enterprise AI inference. The new version adds native GPU virtualization and expanded model governance capabilities, helping enterprises improve GPU utilization while managing model usage, quotas, access control, and security audits across AI applications.

As enterprise AI moves from pilots to production, organizations are running more diverse model workloads, including LLMs, OCR, ASR, embedding, rerank, and other task-specific models. GPU passthrough remains important for high-performance LLM inference, but lightweight and high-concurrency small models can leave GPU memory and compute capacity underused when each workload occupies a full GPU.

Neutree 1.1 adds native vGPU support on top of existing GPU passthrough and logical isolation capabilities. Users can enable GPU virtualization as needed and split GPU resources by memory and compute capacity, allowing one GPU to run multiple model instances for workloads such as OCR, speech, embedding, rerank, and multi-service concurrent inference. For performance-sensitive LLM workloads, users can continue using GPU passthrough to access full-card resources.

The release also provides a global view of node-level GPU usage, helping administrators allocate, schedule, and split resources based on actual demand. With hard-isolated resource partitioning, multiple model instances can run on the same GPU without interfering with each other, improving utilization while maintaining predictable service behavior.

Neutree 1.1 also extends its model gateway with a unified governance layer for internal and external models. As model services are connected to more business systems, platform teams need centralized visibility into usage, quotas, access permissions, and request-level traceability. Neutree helps teams manage token usage, request activity, API key quotas, rate limits, concurrency limits, model access scopes, access logs, and security audits without changing existing application calling patterns.

Neutree is a key component of Arcfra’s agentic AI infrastructure for AI inference. Together with Arcfra Enterprise Cloud Platform, it helps enterprises build production-grade, high-performance, and governable model inference infrastructure across compute, storage, Kubernetes, and observability layers.

Foxconn, the world’s largest electronics manufacturer, was among the first customers to try Neutree. By using its existing Arcfra infrastructure as a production-grade AI foundation, Foxconn adopted Neutree to streamline model delivery and unify compute and model resource management.

Neutree 1.1 is now open source on GitHub. For Neutree Enterprise, contact Arcfra.

View original content:https://www.prnewswire.com/apac/news-releases/arcfra-releases-neutree-1-1-to-help-enterprises-optimize-gpu-utilization-and-govern-ai-inference-at-scale-302830475.html

SOURCE Arcfra

Continue Reading

Trending